跳至主要内容
临床试验/NCT05507840
NCT05507840尚未招募不适用

Photobiomodulation for Dry Age Related Macula Degeneration

Oslo University Hospital0 个研究点目标入组 121 人开始时间: 2022年12月1日最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
121
主要终点
Percentage of patients that develope late AMD in the study eye compared with control after 3 years of follow-up

研究概览

简要总结

The study will investigate the effect of photobiomodulation treatment on the risk of developing late age related macula degeneration (AMD) in the study eye in patients with wet AMD in the fellow eye.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Care Provider)

入排标准

年龄范围
50 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • patients with dry AMD in the study eye and wet AMD in the control eye

排除标准

  • Geographic atrophy of the central macular region at enrolment
  • Previous/ active wet AMD in the study eye
  • A history of epilepsy
  • Retinal diseases apart from AMD
  • Significant media opacities
  • Cataracts worse than grade 2 (LOCS III classification)
  • Change in AREDS 2 supplements (vitamins) 1 month before the study and during the study trial was allowed.
  • Ongoing systemic medications that are photosensitizing (e.g. tetracyclins)
  • Systemic medications during the last 6 months that can cause deposits in the macular region (hydroxychloroquine, amiodarone)
  • Unable to give informed consent
  • Unable to cooperate with the treatment and follow-up

结局指标

主要结局

Percentage of patients that develope late AMD in the study eye compared with control after 3 years of follow-up

时间窗: 3 years

次要结局

未报告次要终点

研究者

发起方
Oslo University Hospital
申办方类型
Other
责任方
Principal Investigator
主要研究者

ANCA ROALD

Principal Investigator, MD dr. med.

Oslo University Hospital

相似试验